Originally Aired: January 30, 2020
Time: 8:00 am PT, 11:00 am ET, 17:00 CET

 

Accelerating research while minimizing workloads has been the driving force behind multiplexing laboratory and clinical assays. Moreover, multiplexed immunoassays can support the successful scale-up of translational research through rapid and reproducible biomarker quantification. Join us for this GEN webinar, where we will examine real-world examples that illustrate how multiomic biomarker assessment can play a pivotal role in the development of new potential therapeutics for cardiovascular disease. Applications discussed will include how biomarker screening has been successfully applied to identify potential novel biofluid-based biomarkers for Parkinson’s Disease in a variety of clinical samples. This webinar has been designed to provide key insights into how multiplexing can accelerate biomarker discovery in both drug development and clinical applications.

 

A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

 

 

Produced with support from:

abcam logo

Michael Tackett

Michael Tackett
Director of Assay
Services, Abcam

Elnaz Atabakhsh

Elnaz Atabakhsh, PhD
Senior Product Manager
Multiplex Assays, Abcam

Paul Wylie

Paul Wylie, PhD
Director of Multiplex
Applications, Abcam